ThermoGenesis Holdings stock analysis
Want to see THMO full AI Analyst Report?
ThermoGenesis Holdings (THMO) Stock Price & Analysis
THMO Stock Chart & Stats
- Day’s Range
- $0.02 - $0.02
- 52-Week Range
- N/A
- Previous Close
- $0.18
- Volume
- N/A
- Average Volume (3M)
- 10.93K
- Market Cap
- $1,585
- Enterprise Value
- $7.20M
- Total Cash (Recent Filing)
- $1.18M
- Total Debt (Recent Filing)
- $6.93M
- Price to Earnings (P/E)
- 0.0
- Beta
- 138.72
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Business Model Strength
ThermoGenesis's focus on automated cell processing technologies positions it well in the growing regenerative medicine field, offering potential for long-term revenue growth as demand for efficient cell therapy solutions increases.
Revenue Generation
The company's diversified revenue streams, including equipment sales and technology licensing, provide a stable foundation for cash generation, supporting its operations and potential growth in the biotechnology sector.
Industry Growth Potential
The expanding regenerative medicine market offers significant growth opportunities for ThermoGenesis, as its technologies align with industry trends towards automation and efficiency in cell therapy manufacturing.
Bears Say
Financial Instability
Negative equity indicates a precarious financial position, raising concerns about the company's solvency and ability to sustain operations without restructuring or additional capital.
Revenue Decline
Declining revenues reflect challenges in maintaining market share or product demand, which could hinder long-term growth prospects and necessitate strategic adjustments to reverse the trend.
Liquidity Issues
Persistent negative cash flows highlight liquidity challenges, potentially limiting the company's ability to invest in growth initiatives or weather financial downturns without external financing.
ThermoGenesis Holdings News
THMO FAQ
What is ThermoGenesis Holdings’s market cap?
When is ThermoGenesis Holdings’s upcoming earnings report date?
How were ThermoGenesis Holdings’s earnings last quarter?
Is ThermoGenesis Holdings overvalued?
Does ThermoGenesis Holdings pay dividends?
What is ThermoGenesis Holdings’s EPS estimate?
How many shares outstanding does ThermoGenesis Holdings have?
What happened to ThermoGenesis Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ThermoGenesis Holdings?
What is the TipRanks Smart Score and how is it calculated?
Company Description
ThermoGenesis Holdings
ThermoGenesis Holdings, Inc., founded in 1986 and based in Rancho Cordova, California, is a global innovator specializing in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. The company's advanced solutions are available across the United States, China, the United Arab Emirates, Vietnam, and other international regions. Its product portfolio encompasses medical devices crucial for automated cell processing. For clinical bio-banking purposes, ThermoGenesis provides the AXP II Automated Cell Separation System, a fully closed system designed for isolating stem and progenitor cells from umbilical cord blood. Complementing this is the BioArchive Automated Cryopreservation System, a robotic, liquid nitrogen-controlled system for both freezing and long-term cryogenic storage of cord blood samples and cell therapeutic products used in clinical environments. In the realm of point-of-care applications, the company offers the XP Point-of-Care System, an automated, sterile, and closed platform that facilitates the rapid processing of autologous stem cells derived from peripheral blood or bone marrow aspirate directly within clinical settings such as surgical centers. Additionally, the PXP-1000 System is another automated, closed solution, engineered for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. For general laboratory use, ThermoGenesis provides its X-Series cell processing products, including X-Lab for cell isolation, the X-Wash System for efficient cell washing and reformulation, and X-Mini for high-efficiency, small-scale cell purification. Beyond its product offerings, the company also delivers contract development and manufacturing (CDMO) services specifically for cell and cell-based gene therapies. Its medical device products are marketed and sold through a network of independent distributors, as well as directly to end-user customers. The company, formerly known as Cesca Therapeutics Inc., officially adopted the name ThermoGenesis Holdings, Inc. in November 2019.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Xiaochun Xu
- Employees
- 25
- Website
- www.thermogenesis.com
- Address
- 2711 Citrus Road, Rancho Cordova, CA, 95742, US









